Shensong Yangxin Capsules in the adjuvant treatment of stable angina pectoris:a Meta-analysis and trial sequential analysis.
10.19540/j.cnki.cjcmm.20190624.503
- Author:
Yuan-Tang XI
1
;
Li-Yi YUAN
2
;
Yuan-Yuan ZENG
2
;
Man-Li YAN
2
;
Xiao-Ru LIANG
2
;
Ai-Ting FENG
2
;
Wei WU
3
Author Information
1. the First School of Clinical Medicine,Guangzhou University of Traditional Chinese Medicine Guangzhou 510405,China.
2. the Second School of Clinical Medicine,Guangzhou University of Traditional Chinese Medicine Guangzhou 510405,China.
3. the First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine Guangzhou 510405,China.
- Publication Type:Journal Article
- Keywords:
Meta-analysis;
Shensong Yangxin Capsules;
randomized controlled trials;
stable angina pectoris;
trial sequential analysis
- MeSH:
Adjuvants, Pharmaceutic;
Angina, Stable;
drug therapy;
C-Reactive Protein;
analysis;
Capsules;
Drugs, Chinese Herbal;
therapeutic use;
Electrocardiography;
Humans;
Lipids;
blood;
Randomized Controlled Trials as Topic
- From:
China Journal of Chinese Materia Medica
2019;44(17):3816-3824
- CountryChina
- Language:Chinese
-
Abstract:
To systemically evaluate the benefits and side effects of Shensong Yangxin Capsules( SYC) in the adjuvant treatment of stable angina pectoris( SAP). Chinese and English databases( PubMed,EMbase,the Cochrane Library,CBM,CNKI,VIP,Wan Fang database) were retrieved to collect the randomized controlled trials( RCTs) about therapeutic efficacy of SYC combined with routine drug( trial group) vs routine drug( control group) in the treatment of SAP. The methodological quality of the RCTs was evaluated based on the cochrane risk of bias assessment tool. The data were extracted and Meta-analyzed by Reviewer Manager 5. 3. TSA 0. 9 software was used for trial sequential analysis( TSA) of the total effective rate of symptoms improvement. A total of 15 RCTs with 1 316 participants were included. RESULTS:: of Meta-analysis showed that the total effective rate of angina symptoms improvement( RR = 1. 15,95% CI[1. 09,1. 21],P<0. 001) of trial group were significantly higher than those of control group,with statistical significance,the total effective rate of electrocardiograms( ECG) improvement( RR = 1. 10,95% CI[0. 94,1. 29],P = 0. 25) of trial group were significantly higher than those of control group,but the difference was not statistically significant. After treatment,the improvement of the total time of 24 h general ischemia( SMD =-1. 21,95%CI[-1. 97,-0. 45],P = 0. 002),the ST-segment depression amplitude( SMD =-1. 30,95%CI [-1. 52,-1. 09],P<0. 001),the duration of angina pectoris attack( SMD =-1. 16,95% CI[-1. 36,-0. 95],P< 0. 001),the angina pectoris attack every week( SMD =-0. 80,95%CI[-1. 10,-0. 50],P<0. 001),the onsumption of nitroglycerin every week( SMD=-0. 72,95%CI[-1. 05,-0. 39],P<0. 001) in the trial group were better than that of the control group,and the difference was statistically significant. Besides,the improvement of the blood lipid and high sensitivity C reactive protein( hs-CRP) in the trial group were better than those of the control group after treatment,and the difference was statistically significant( P< 0. 001). Funnel plots and Egger's linear regression showed that there was no publication bias. By sensitivity analysis,it showed that the results of this study were stable and reliable. No obvious adverse drug reactions were observed in all studies. TSA analysis showed that the evidence of Meta-analysis was reliable. SYC combined with routine Western medicine treatment for SAP can improve the total effective rate of angina pectoris,reduce 24 h total ischemia time,ST segment depression amplitude,duration of angina pectoris attack,frequency of angina pectoris attack and nitroglycerin dosage,and also can improve blood lipid and hs-CRP levels.
